|
Total patients
|
(n = 39)
|
|---|
|
Age
| | |
| |
≤ 69 years
|
20 (51.3%)
|
| |
> 69 years
|
19 (48.7%)
|
|
Tumor stage
| | |
| |
cT1
|
12 (30.8%)
|
| |
cT2
|
5 (12.8%)
|
| |
cT3a
|
13 (33.4%)
|
| |
cT3b
|
7 (17.9%)
|
| |
cT4
|
2 (5.1%)
|
|
Gleason score
| | |
| |
2–6
|
20 (51.3%)
|
| |
7
|
13 (33.3%)
|
| |
8–10
|
6 (15.4%)
|
|
Pre-treatment PSA
| | |
| |
≤ 10 ng/mL
|
20 (51.3%)
|
| |
>10 ng/mL
|
19 (48.7%)
|
|
Risk group
| | |
| |
Low
|
7 (17.9%)
|
| |
Intermediate
|
8 (20.5%)
|
| |
High
|
24 (61.6%)
|
|
Hormonal therapy
| | |
| |
no
|
10 (25.6%)
|
| |
yes
|
29 (74.4%)
|
|
Median FU months† (range)
| |
29 (22–40)
|
- Abbreviations: PSA = prostate- specific antigen; FU = follow-up;
- †period after completion of treatment.
